[Platelet aggregation inhibitor in general practice. Every 3rd infarct prevented--reinfarction rate cut in half].

Abstract

Depending on their mode of action, pharmaceuticals with an antithrombocytic effect are divided into five groups. In the doctor's office, acetylsalicylic acid (ASA) and the thienopyridines, such a ticlopidine and clopidogrel predominate. Acetylsalicylic acid should be considered for primary prevention in patients over 50 with a marked cardiovascular risk profile. In the secondary prophylaxis of myocardial infarction, life-long ASA treatment continues to be the treatment of choice. As an alternative, however, clopidogrel may be applied. A combination of acetylsalicylic acid and clopidogrel is recommended for patients who have been implanted with a stent. In patients with acute coronary syndrome, this regimen is superior to monotherapy with acetylsalicylic acid. In comparison with ticlopidine, clopidogrel has a more rapid onset of action, and has fewer side effects. In patients with an acute coronary syndrome and an elevated risk glycoprotein IIb/IIIa antagonists have proved highly effective.

• Authors: M Fliri
• Journal: MMW Fortschritte der Medizin (MMW Fortschr Med) Vol. 144 Issue 33-34 Pg. 38-41 (Aug 22 2002) ISSN: 1438-3276 [Print] Germany
• Vernacular Title: Thrombozytenaggregationshemmer in der Praxis. Jeder dritte Infarkt verhütet--Reinfarktrate halbiert.
• PMID: 12380142 (Publication Type: English Abstract, Journal Article)

Chemical References

• Platelet Aggregation Inhibitors
• Aspirin

Topics

• Aspirin (adverse effects, therapeutic use)
• Humans
• Myocardial Infarction (mortality, prevention & control)
• Platelet Aggregation Inhibitors (adverse effects, classification, therapeutic use)
• Recurrence
• Survival Rate
• Treatment Outcome